Table 4.
Univariate and multivariable Cox proportional hazards analysis for distant failure
| Univariate analysis | Multivariable analysis | |||
|---|---|---|---|---|
| Prognostic factor | Hazard ratio (95 % CI) | P value | Hazard ratio (95 % CI) | P value |
| Age (continuous) | 1.00 (0.98-1.02) | 0.872 | ||
| Age (>70 or ≤ 70)a | 1.10 (0.59-2.07) | 0.760 | ||
| Gender (female or male) | 0.89 (0.52-1.53) | 0.675 | ||
| KPS (>80 or ≤ 80) | 3.20 (1.21-8.48) | 0.019 | 4.37 (1.58-12.06) | 0.004 |
| Extracranial disease (absent vs. stable/active) | 2.63 (1.04-6.68) | 0.041 | 2.60 (1.29-5.27) | 0.008 |
| Extracranial disease (absent/stable vs. active) | 2.58 (1.33-5.01) | 0.005 | ||
| No. of lesions | ||||
| 1 | 1.00 | |||
| 2-3 | 3.13 (1.48-6.61) | 0.003 | 2.30 (1.08-4.91) | 0.032 |
| >3 | 5.93 (2.65-13.26) | <.0001 | 5.27 (2.40-11.57) | <.0001 |
| BRAF (WT vs. mutation) | 0.89 (0.49-1.63) | 0.713 | ||
| Metastases volume (<1 cc vs. ≥1 cc) | 1.47 (0.85-2.54) | 0.171 | ||
| Treatment volume (<4 cc vs. ≥4 cc) | 1.70 (0.99-2.92) | 0.054 | ||
| Peri-SRS systemic therapy (no vs. yes) | 1.48 (0.87-2.54) | 0.150 | ||
| Post-SRS systemic therapy (no vs. yes) | 0.74 (0.29-1.89) | 0.534 | ||
Abbreviations: BRAF B-Raf proto-oncogene, CI 95 % confidence interval, KPS Karnosfky performance status, peri-SRS at the time of stereotactic radiosurgery, post-SRS after stereotactic radiosurgery, WT wild-type; acut-off at the upper quartile of age